-
平臺編號：bio-68454
-
國際編號：CRL-2319?
-
細(xì)胞信息： HCC1007 BL
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
HCC1007 BL
年限：67 years adult
細(xì)胞形態(tài)：淋巴樣
細(xì)胞類型：B淋巴細(xì)胞
是否是腫瘤細(xì)胞：0
物種來源：人
生長狀態(tài)：懸浮生長，多細(xì)胞聚集
運輸方式：凍存運輸
數(shù)量：大量
器官來源：外周血
ATCC Number：CRL-2319?
規(guī)格：48T Designations: HCC1007 BL
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:2 [Cells contain Herpes virus (Epstein-Barr Virus) ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications:HCC1008 was initiated from a 67 year old Black female with a TNM stage IIA, grade 3 metastatic carcinoma; metastatic site: lymph node.
Age: 67 years adult
Gender: female
Ethnicity: Black
Comments:HCC1007BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1008.
HCC1008 was initiated from a 67 year old Black female with a TNM stage IIA, grade 3 metastatic carcinoma; metastatic site: lymph node.
HCC1008 is available as CRL-2320.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternately, cultures can be established by centrifugation with subsequent resuspension at 3 to 5 X 10 exp5 viable cells/ml. Maintain cell density between 3 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
tumor cell line established from the same patient:ATCC CRL-2320
purified DNA:ATCC CRL-2319D
purified RNA:ATCC CRL-2319R
References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
細(xì)胞形態(tài)：淋巴樣
細(xì)胞類型：B淋巴細(xì)胞
是否是腫瘤細(xì)胞：0
物種來源：人
生長狀態(tài)：懸浮生長，多細(xì)胞聚集
運輸方式：凍存運輸
數(shù)量：大量
器官來源：外周血
ATCC Number：CRL-2319?
規(guī)格：48T Designations: HCC1007 BL
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:2 [Cells contain Herpes virus (Epstein-Barr Virus) ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications:HCC1008 was initiated from a 67 year old Black female with a TNM stage IIA, grade 3 metastatic carcinoma; metastatic site: lymph node.
Age: 67 years adult
Gender: female
Ethnicity: Black
Comments:HCC1007BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1008.
HCC1008 was initiated from a 67 year old Black female with a TNM stage IIA, grade 3 metastatic carcinoma; metastatic site: lymph node.
HCC1008 is available as CRL-2320.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternately, cultures can be established by centrifugation with subsequent resuspension at 3 to 5 X 10 exp5 viable cells/ml. Maintain cell density between 3 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
tumor cell line established from the same patient:ATCC CRL-2320
purified DNA:ATCC CRL-2319D
purified RNA:ATCC CRL-2319R
References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
